Trastuzumab deruxtecan for HER2-overexpressing colorectal cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see if the study drug, trastuzumab deruxtecan, is safe and effective for fighting your cancer. We will also compare 2 different dose levels.

What is the Condition Being Studied?

Colorectal Adenocarcinoma

Who Can Participate in the Study?

Adults with colorectal adenocarcinma who:
- Have advanced or metastatic disease
- Failed standard-of-care therapy

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Get the study drug, trastuzumab deruxtecan, by I.V. once every 3 weeks
- Give blood and urine samples
- Have regular CT or MRI scans

Study Details

Full Title
[DS8201-A-U207] A phase 2, multicenter, randomized study of trastuzumab deruxtecan in subjects with HER2-overexpressing locally advanced, unresectable or metastatic colorectal cancer (Destiny-CRC02)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00107696
NCT: NCT04744831
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698